Roche chooses Veeva Vault PromoMats for digital asset management and content
pharmafile | December 4, 2018 | News story | Manufacturing and Production, Medical Communications | Roche, pharma, veeva
Today, at the 2018 Veeva Commercial & Medical Summit Europe, Roche (SWX:ROG) announced that it would be adopting Veeva Systems (NYSE:VEEV) Vault PromoMats as its global content and digital asset management solution.
This is part of Roche’s plans to reduce time to market when delivering commercial and medical content, and will help the company to better manage the lifecycles of digital assets, reduce expensive duplication of assets, maintain control of its brand image, and remain compliant in a complex regulatory environment.
Commenting on the announcement, John Chinnici, vice president of commercial content at Veeva, said: “Vault PromoMats gives the life sciences industry a single solution to easily create and distribute content with integrated capabilities to manage rich digital assets. We are proud to partner with Roche on this important initiative to speed time to market for its commercial and medical content.”
By implementing Vault PromoMats, Roche will eliminate the need to move, duplicate, and manage content and digital assets across multiple systems. This will deliver improved visibility, control, and compliance across the digital supply chain.
As the first and only application to combine digital asset management with medical, legal, and regulatory review, Veeva Vault PromoMats provides a single solution to streamline content management and distribution. It combines digital asset management with review and distribution capabilities, providing the only solution built for life sciences. Easy review and approval, plus automated content distribution and withdrawal across channels, ensures complete visibility and control of all materials.
More than 200 life sciences companies across 165+ countries rely on Veeva Vault PromoMats for commercial content and digital asset management.
Matt Fellows
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …
Roche candidate shows early promise for treating haemophilia A
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational …
